MRI Screening of Placenta Adhesion Abnormalities — DIANE  

Placenta; Implantation Clinical Trial

Official title: MRI Screening of Placenta Adhesion Abnormalities

Status Recruiting

Clinical Trial Summary

Placenta Adhesion Abnormalities (PAA) are the consequence of an excessive invasion of the placenta within the myometrium. PAA are related to severe maternal pregnancy outcomes, especially in case of incidental discovery during delivery that increase the risk of intraoperative massive bleeding, hysterectomy and even maternal death. Ultrasound is the standard modality for diagnosing PAA, but Magnetic Resonance Imaging (MRI) has been increasingly performed in the case of inconclusive sonographic findings. However, standard morphological MRI sequences appear as insufficient to improve the sensitivity and specificity values for detecting PAA, while quantitative MRI may be more efficient.

The main objective of this study is to characterize the diagnostic performance of quantitative MRI parameters (mainly Apparent Diffusion Coefficient, T2 and T2*) reflecting placental perfusion and/or oxygenation at high field, without injection of gadolinium-based agent, for the detection of PAA in women with ongoing pregnancy between 30 and 38 weeks of gestation with risk factors for PPA.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Congenital Abnormalities
• Placenta; Implantation

• NCT number: NCT04328532
• Study type: Interventional
• Source: Central Hospital, Nancy, France
• Contact: Charline BERTHOLDT, MI
• Phone: +33 3 83 34 43 12
• Email: c.bertholdt@chru-nancy.fr
• Status: Recruiting
• Phase: N/A
• Start date: October 21, 2020
• Completion date: October 21, 2026